

Affitech A/S Annual General Meeting 2010

Attachment 4

Keith McCullagh, Chairman

Nationality: English

Age: 67

Elected: 2009,

Keith McCullagh holds 5,419,502 warrants in the Company
Independent

Keith McCullagh is Chairman of the boards of directors of Clavis Pharma AS (Norway), Pharmacy 2U Limited and Xention Limited, (both UK).

Keith McCullagh is a biotech entrepreneur having co-founded and built three life science companies and been instrumental in the development of the European bioscience industry through the establishment of of the UK Bioindustry Association and the formation of Europa Bio.

Keith McCullagh is co-founder and Chairman of the Board of On Media Group pls. He is Chairman of the Board of Clavis Pharma AS (Norge), Pharmacy 2U Limited og Xention Limited (both UK)

Pål Rødseth

Nationality: Norwegian

Age: 41

Elected: 2009

Pål Rødseth is partner in Ferd Venture, Ferd AS owns 15.78 % of the shares in Affitech A/S

Pål Rødseth is member of the Board of Directors of Cinevation AS, Haukebø & Rødseth AS, Molde Auto AS, Nanoradio AB, Oxymonron AS, Solbakken Finans AS, Vensafe AS (all Norway).

Pål Rødseth has broad experience from venture capital investments from the Nordic region as well as the UK and US.

Through Ferd Venture Pål Rødseth is a board member of several portfolio companies.

Prior to joining Ferd Venture Pål Rødseth was Investment Director with Add Partners in London, a pan-European venture capital fund.

Arne Handeland

Nationality: Norwegian

Age: 46

Elected: 2009

Arne Handeland is partner in Verdane Capital. Verdane Capital VI and Verdane Private Equity together own 17.17 % of the shares in Affitech A/S

Arne Handeland is Chairman of the Board of Naudholmen A/S, and he is member of the Board of Directors of Industriverktøy AS, IV Techmould Holding, Biotec Pharmacon ASA, Holmen Industri Invest 1AS, Teamtec AS, Norge and Teamtec Invest AS (all Norway).

Arne Handeland has more than 10 years experience from the venture capital investments primarily from the Nordic region. At Verdane Arne focuses on the biotechnology and industrial sectors. Prior to joining Verdane Capital he was an Investment Manager with SND Invest. Arne Handeland has also been CEO of Biotec Holding AS.

Ole Steen Andersen, Deputy Chairman

Nationality: Danish

Age: 64

Elected: 2007

Ole Steen Andersen owns 80.000 shares in Affitech A/S

Independent

Ole Steen Andersen has been Executive Vice President since 1994 and Chief Financial Officer since 2000 in Danfoss A/S.

Before Danfoss Ole Steen Andersen was President in NKT Holding A/S.

Ole Steen Andersen is Chairman of the Board of Directors in BB Electronics, Dansk Venture Kapital and Private Equity Association, Sanistål A/S and HedgeCorp A/S. He is a member of the Board of Directors in AVK Holding, SPEAS A/S, den selvejende institution Sandbjerg Gods HTCC Inc. Invitel Holding A/S, Scandinavian private Equity A/S.

Ole Steen Andersen is member of the Management of Slotsbakken Holding ApS.

Steinar J. Engelsen

Nationality: Norwegian

Age: 60

Elected: 2009

Steinar Engelsen is partner in Teknoinvest. Teknoinvest VII owns 8,68% of the shares in Affitech A/S

Steinar J. Engelsen joined Teknoinvest AS, a Norwegian Venture Capital company in 1996.

Prior to joining Teknoinvest, Steinar J. Engelsen was Senior Vice President R&D, Nycomed Pharma, with responsibility for research, preclinical and clinical development and medical affairs.

Steinar J Engelsen was Research Associate at the Department of Chemistry and was later Research Fellow at Rikshospitalet University Hospital, Oslo.

Steinar Engelsen serves as board member of Insmid, Inc. (NASDAQ:INSM) and Capnia Inc. (USA)

Michel L. Pettigrew

Nationality: Canadian

Age: 56

Elected: 2009

Michel Pettigrew owns 16.000 shares in Affitech A/S

Independent

Michel Pettigrew is President of the Executive Board & Chief Operating Officer of the Ferring Group.

He joined the Ferring Group in May 2001 and is currently responsible for all commercial, global marketing, business development, medical services and technical operations activities of the company. Prior to joining Ferring Michel Pettigrew had a 21-year career at Bristol-Myers Squibb.
